Loading...
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
BACKGROUND: An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adults. OBJECTIVES: To determine the pharmacokinetic profile of extended-release amantadine...
Saved in:
| Published in: | CNS Drugs |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6669187/ https://ncbi.nlm.nih.gov/pubmed/31342404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-019-00651-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|